How are you feeling today? Keep up to date on news and stories related to healthcare here!
Johnson & Johnson plans to enroll 60,000 participants in its Phase 3 trials. Dr. Anthony Fauci and other top U.S. health officials are scheduled to testify before a Senate panel today. — NYT: Top Stories
Immetas Therapeutics Announces Series A Financing to Advance Research on Inflammation Pathways in Aging and Develop Therapeutics for Cancer and Inflammatory Disease, EAST HANOVER, N.J.–(BUSINESS WIRE)–Immetas Therapeutics today announced it has raised a Series A financing of $11 million to advance research
Experts weigh in on what the future may hold amid the pandemic. — ABC News: Top Stories
The novel coronavirus was apparently no match for a 102-year-old woman in New Hampshire. FOX News: Madeline Farber
Clinical trials have not included children, so vaccines for them may not arrive until the next school year, while adults may get theirs by summer. — NYT: Top Stories
Pathline Labs Doubles Testing Capacity for COVID-19, Adds Major Clients Throughout U.S., Testing through Pathline Labs is now available nationwide RAMSEY, N.J.–(BUSINESS WIRE)–Pathline Labs, a leading provider of sub-specialized anatomic pathology, has expanded its COVID-19 testing capabilities across the country while maintaining
The staggering toll of the pandemic comes as at least 73 countries are seeing surges in newly detected cases. — NYT: Top Stories
LYNPARZA is the Only PARP Inhibitor to Demonstrate Improved Overall Survival in Metastatic Castration-Resistant Prostate Cancer KENILWORTH, N.J.–(BUSINESS WIRE)–$MRK #MRK–AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced final results from the Phase 3 PROfound
Researchers Share New Data for Vibostolimab (MK-7684), Merck’s Anti-TIGIT Therapy, as Monotherapy and in Combination With KEYTRUDA® (pembrolizumab); First-Time Results for First-in-Class MK-4830 (Anti-ILT4 Therapy); and Late-Breaking Data for MK-6482 (HIF-2α Inhibitor) Merck to Initiate Phase 3 Study of Vibostolimab in Non-Small